| Literature DB >> 34793741 |
Saad B Omer1, Regina M Benjamin2, Noel T Brewer3, Alison M Buttenheim4, Timothy Callaghan5, Arthur Caplan6, Richard M Carpiano7, Chelsea Clinton8, Renee DiResta9, Jad A Elharake10, Lisa C Flowers11, Alison P Galvani12, Rekha Lakshmanan13, Yvonne A Maldonado14, SarahAnn M McFadden10, Michelle M Mello15, Douglas J Opel16, Dorit R Reiss17, Daniel A Salmon18, Jason L Schwartz19, Joshua M Sharfstein20, Peter J Hotez21.
Abstract
Since the first case of COVID-19 was identified in the USA in January, 2020, over 46 million people in the country have tested positive for SARS-CoV-2 infection. Several COVID-19 vaccines have received emergency use authorisations from the US Food and Drug Administration, with the Pfizer-BioNTech vaccine receiving full approval on Aug 23, 2021. When paired with masking, physical distancing, and ventilation, COVID-19 vaccines are the best intervention to sustainably control the pandemic. However, surveys have consistently found that a sizeable minority of US residents do not plan to get a COVID-19 vaccine. The most severe consequence of an inadequate uptake of COVID-19 vaccines has been sustained community transmission (including of the delta [B.1.617.2] variant, a surge of which began in July, 2021). Exacerbating the direct impact of the virus, a low uptake of COVID-19 vaccines will prolong the social and economic repercussions of the pandemic on families and communities, especially low-income and minority ethnic groups, into 2022, or even longer. The scale and challenges of the COVID-19 vaccination campaign are unprecedented. Therefore, through a series of recommendations, we present a coordinated, evidence-based education, communication, and behavioural intervention strategy that is likely to improve the success of COVID-19 vaccine programmes across the USA.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34793741 PMCID: PMC8592561 DOI: 10.1016/S0140-6736(21)02507-1
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321
COVID-19 vaccines FDA-approved for emergency use in the USA as of June 14, 2021
| Pfizer-BioNTech | Dec 11, 2020 | mRNA | Two | 12 years and older |
| Moderna | Dec 18, 2020 | mRNA | Two | 18 years and older |
| Janssen (Johnson & Johnson) | Feb 27, 2021 | Viral vector (adenovirus type 26) | One | 18 years and older |
FDA=US Food and Drug Administration.
The Pfizer-BioNTech vaccine received full FDA approval on Aug 23, 2021.
Proposed interventions to increase vaccine uptake
| Centralised reminder | Children (aged <18 years | Adolescent and adult vaccination | Challenges with interoperability between COVID-19 vaccine registries and electronic health records might limit implementation of the reminder; reminders that use contact information in immunisation registries will have minimal penetration into adult populations because not all states input adult immunisations into online registries |
| Default appointments | Adults | Childhood and adolescent vaccination | Would not reach those who do not already have established providers, which might correspond to high-risk populations (eg, the homeless) |
| Standing orders | Adults in hospitals and nursing facilities | Childhood and adolescent vaccination | Anticipated increased scepticism or questions regarding COVID-19 vaccines compared with other vaccines might make standing orders less effective |
| Presumptive provider communication | Children and adolescents | Adult vaccination or when there is not yet a trusted relationship with the provider | Questions or scepticism around vaccine release and informed consent for COVID-19 vaccination might make this approach less useful |
| Onsite vaccination | Adults in worksites, children in school health centres; school mass vaccination days | Adolescent vaccination | Both the Pfizer-BioNTech and Moderna vaccines require two doses for full immunisation |
| Incentives and mandates | Applicable to most vaccines | Past mandates have generally applied only to specific groups; acceptability of mandates for an entire population is unknown | Might encounter political barriers and fuel disinformation efforts from anti-vaccine and other counter-activism movements |
Interventions are shown ordered to match a clinical encounter.
Childhood vaccines generally refer to vaccines administered to very young children (often from birth to children entering kindergarten [aged 5–6 years]); however, currently, there are no COVID-19 vaccines authorised or approved for use in children younger than 12 years.